In This Article:
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.
Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.
Why Investors Should Pay Attention to This Value Stock
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.
Teva Pharmaceutical Industries Ltd. (TEVA)
Headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs (includes biosimilars and over-the-counter (“OTC”) products), as well as active pharmaceutical ingredients (APIs) in North America, Europe, Latin America, India, and Israel. Teva’s generic product portfolio includes tablets, capsules, liquids, ointments, creams, transdermal patches, injectables, and inhalants. Teva plans to separate its API unit into a standalone business unit through a sale.
TEVA boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Teva Pharmaceutical Industries Ltd. are trading at a forward earnings multiple of 5.8X, as well as a PEG Ratio of 1.4, a Price/Cash Flow ratio of 4.4X, and a Price/Sales ratio of 1X.
Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.01 to $2.55 per share. TEVA has an average earnings surprise of 2.2%.
TEVA should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).